BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 19303818)

  • 1. Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions.
    Pachiadakis I; Chokshi S; Cooksley H; Farmakiotis D; Sarrazin C; Zeuzem S; Michalak TI; Naoumov NV
    Clin Immunol; 2009 Jun; 131(3):415-25. PubMed ID: 19303818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation and functional analysis of circulating dendritic cells from hepatitis C virus (HCV) RNA-positive and HCV RNA-negative patients with chronic hepatitis C: role of antiviral therapy.
    Tsubouchi E; Akbar SM; Murakami H; Horiike N; Onji M
    Clin Exp Immunol; 2004 Aug; 137(2):417-23. PubMed ID: 15270861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
    Cramp ME; Rossol S; Chokshi S; Carucci P; Williams R; Naoumov NV
    Gastroenterology; 2000 Feb; 118(2):346-55. PubMed ID: 10648463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection.
    Miyatake H; Kanto T; Inoue M; Sakakibara M; Kaimori A; Yakushijin T; Itose I; Miyazaki M; Kuzushita N; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
    J Viral Hepat; 2007 Jun; 14(6):404-12. PubMed ID: 17501761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance.
    Aberle JH; Perstinger G; Weseslindtner L; Sinzinger U; Gurguta C; Steindl-Munda P; Kundi M; Popow-Kraupp T; Ferenci P; Holzmann H
    J Infect Dis; 2007 May; 195(9):1315-9. PubMed ID: 17397001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribavirin downmodulates inducible costimulator on CD4+ T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance.
    Atsukawa M; Nakatsuka K; Kobayashi T; Shimizu M; Tamura H; Harimoto H; Takahashi H; Sakamoto C
    J Gastroenterol Hepatol; 2012 Apr; 27(4):823-31. PubMed ID: 21871023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C patients.
    Itose I; Kanto T; Inoue M; Miyazaki M; Miyatake H; Sakakibara M; Yakushijin T; Oze T; Hiramatsu N; Takehara T; Kasahara A; Katayama K; Kato M; Hayashi N
    J Med Virol; 2007 May; 79(5):511-21. PubMed ID: 17385691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*.
    González V; Padilla E; Diago M; Giménez MD; Solà R; Matas L; Montoliu S; Morillas RM; Pérez C; Planas R
    J Viral Hepat; 2005 Sep; 12(5):481-7. PubMed ID: 16108762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy.
    Tang KH; Herrmann E; Cooksley H; Tatman N; Chokshi S; Williams R; Zeuzem S; Naoumov NV
    J Hepatol; 2005 Nov; 43(5):776-82. PubMed ID: 16139918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.
    Poynard T; Colombo M; Bruix J; Schiff E; Terg R; Flamm S; Moreno-Otero R; Carrilho F; Schmidt W; Berg T; McGarrity T; Heathcote EJ; Gonçales F; Diago M; Craxi A; Silva M; Bedossa P; Mukhopadhyay P; Griffel L; Burroughs M; Brass C; Albrecht J;
    Gastroenterology; 2009 May; 136(5):1618-28.e2. PubMed ID: 19208349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
    Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
    Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals.
    Kanto T; Hayashi N; Takehara T; Tatsumi T; Kuzushita N; Ito A; Sasaki Y; Kasahara A; Hori M
    J Immunol; 1999 May; 162(9):5584-91. PubMed ID: 10228041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients.
    Capa L; Soriano V; García-Samaniego J; Nuñez M; Romero M; de Mendoza C; Cascajero A; Muñoz F; González-Lahoz J; Benito JM
    Antivir Ther; 2007; 12(4):459-68. PubMed ID: 17668554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N; Giannelli G; Antonaci A; Antonaci S
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
    Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
    Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response.
    Carlsson T; Reichard O; Norkrans G; Bläckberg J; Sangfelt P; Wallmark E; Weiland O
    J Viral Hepat; 2005 Sep; 12(5):473-80. PubMed ID: 16108761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin.
    Gallegos-Orozco JF; Loaeza-del Castillo A; Fuentes AP; García-Sandoval M; Soto L; Rodríguez R; Gutiérrez-Ruíz MC; Gutiérrez-Reyes G; Bonder A; Olivera MA; Kershenobich D
    Liver Int; 2005 Feb; 25(1):91-5. PubMed ID: 15698404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus.
    Rigopoulou EI; Abbott WG; Williams R; Naoumov NV
    Antiviral Res; 2007 Jul; 75(1):36-42. PubMed ID: 17210188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.